Ashina, Håkan http://orcid.org/0000-0002-6268-727X
Al-Khazali, Haidar Muhsen
Iljazi, Afrim
Ashina, Sait
Amin, Faisal Mohammad
Lipton, Richard B.
Schytz, Henrik Winther
Funding for this research was provided by:
Rigshospitalet Research Foundation (F-23340-02)
International Headache Society
Article History
Received: 17 May 2021
Accepted: 5 July 2021
First Online: 26 July 2021
Declarations
:
: Informed written consent was obtained from each patient before conducting any study-related procedures. The study protocol was approved by the relevant ethics committee and institutional review board.
: Not applicable.
: The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Sait Ashina has received honoraria from Allergan and Teva and consultant fees from Amgen and Allergan. Sait Ashina received honoraria for consulting for Allergan, Amgen, Eli Lilly, Novartis, Promius, Satsuma, Supernus, and Theranica. Faisal Mohammad Amin is a lecturer or scientific advisor for Teva, Eli Lilly, Lundbeck, and Novartis. Messoud Ashina has received personal fees from Alder BioPharmaceuticals, Allergan, Amgen, Eli Lilly, Novartis, and Teva. MA also participated in clinical trials as the principal investigator for Alder, Amgen, electroCore, Novartis, and Teva. Richard B. Lipton serves on the editorial boards of Neurology and Cephalalgia and as senior advisor to Headache; has received research support from the National Institutes of Health (NIH); receives support from the Migraine Research Foundation and the National Headache Foundation; has reviewed for the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS); serves as consultant, advisory board member, or has received honoraria from Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Boston Scientific, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeuraTherapeutics, GlaxoSmithKline, Merck, Novartis, Teva, and Vedanta; receives royalties from Wolff’s Headache and Informa; holds stock options in eNeura Therapeutics and Biohaven. Henrik Winther Schytz received speaking fees from Novartis and Teva. The other authors declare no conflicts of interest.